Article | October 26, 2023

Good Manufacturing Practices (cGMP): When Do They Apply?

Source: Advarra

By Amanda Bourgeois, Associate Director and Leslie Paul, Associate Director

GettyImages-1026858958 manufacturing worker

The application of current Good Manufacturing Practices (cGMP) regulations during the development of a new drug can be a source of uncertainty for clinical project teams. Commencing the incorporation of cGMPs in the drug development process from its inception serves a dual purpose: safeguarding the well-being of clinical trial participants and establishing a sturdy foundation for a comprehensive quality management system (QMS). Embracing quality systems at an early stage facilitates a seamless assimilation of processes, alleviating organizational burdens. Moreover, this proactive approach guarantees enhanced oversight, fosters a culture centered on quality, and mitigates the likelihood of noncompliance. This proactive stance not only aids the organization in its progression toward commercialization but also acts as a vital assurance for a successful pre-approval inspection.

In this article, the author explores expectations set by the U.S. Food and Drug Administration (FDA) regarding the implementation of cGMP standards for investigational drugs. Understanding these expectations is essential for ensuring the quality and safety of emerging pharmaceutical products.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader